title: Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer.
abstract: The role of nuclear medicine physicians in the multidisciplinary team for the management of patients with prostate cancer has been restricted because of a lack of available tools. The only drugs approved to relieve pain related to bone metastases were β-emitting radiopharmaceuticals. These drugs did not prove to prolong survival when used as single agent and resulted associated with important adverse events. This situation has changed with the introduction of radium 223 because of evidence of improved survival in patients, the good safety profile and the opportunity to avoid clonal selection of tumor cells. Cooperation among physicians involved in cancer management will lead to improvements in the treatment of bone metastases due to prostate cancer and is thought to extend to other tumor types.
authors: Division of Nuclear Medicine, University Hospital of Pisa, Pisa, Italy.
authors: Elisa
authors: E
authors: Borsò
authors: Giuseppe
authors: G
authors: Boni
authors: Luca
authors: L
authors: Galli
authors: Sergio
authors: S
authors: Ricci
authors: Azzurra
authors: A
authors: Farnesi
authors: Sara
authors: S
authors: Mazzarri
authors: Claudia
authors: C
authors: Cianci
authors: Giuliano
authors: G
authors: Mariani
authors: Alfredo
authors: A
authors: Falcone
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D006801:Humans; D008297:Male; D059408:Pain Management; D018579:Patient Selection; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000473:pathology; D011868:Radioisotopes / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D011883:Radium / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D011868:Radioisotopes; D019275:Radiopharmaceuticals; C581106:radium Ra 223 dichloride; D011883:Radium
keywords: castration-resistant prostate cancer; nuclear medicine physician; radiopharmaceuticals; radium 223 dichloride; α-emitting; β-emitting